Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
Abstract Aim To evaluate the efficacy and impact of long-acting injectable (LAI) aripiprazole in patients with schizophrenia with a coexisting substance use disorder (SUD). Patients and methods A multicenter, observational, descriptive and retrospective study was conducted in patients with a DSM-5 d...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2020-02-01
|
| Series: | Drugs - Real World Outcomes |
| Online Access: | https://doi.org/10.1007/s40801-020-00178-8 |
| _version_ | 1818676743080247296 |
|---|---|
| author | Nestor Szerman Ignacio Basurte-Villamor Pablo Vega Jose Martinez-Raga Carlos Parro-Torres Julia Cambra Almerge Lara Grau-López Mario De Matteis Francisco Arias |
| author_facet | Nestor Szerman Ignacio Basurte-Villamor Pablo Vega Jose Martinez-Raga Carlos Parro-Torres Julia Cambra Almerge Lara Grau-López Mario De Matteis Francisco Arias |
| author_sort | Nestor Szerman |
| collection | DOAJ |
| description | Abstract Aim To evaluate the efficacy and impact of long-acting injectable (LAI) aripiprazole in patients with schizophrenia with a coexisting substance use disorder (SUD). Patients and methods A multicenter, observational, descriptive and retrospective study was conducted in patients with a DSM-5 diagnosis of schizophrenia who had a coexisting SUD and were treated with LAI-aripiprazole. Disease severity was evaluated with the Clinical Global Impression (CGI) severity scale for schizophrenia, daily functioning and disability were evaluated with the World Health Organisation Disability Assessment Scale (WHODAS-2.0), and the severity of the addiction was evaluated with the Severity of Dependence Scale (SDS). Results The sample included 40 patients. Overall, after 6 months of treatment with LAI-aripiprazole at a dose of 400 mg/4 weeks in 77.5% of the patients, we observed significant improvement in the psychopathological symptoms, with a reduction of over 30% in the scores of the five CGI-severity scales. The WHODAS-2.0 mean (standard deviation) score was also significantly reduced from 57.6 (8.2) to 42.3 (4.3) points (p < 0.001). Regarding SUDs, after 6 months of treatment, substance use was stopped in 5 of the 9 patients with cocaine use disorder and in 3 of the 16 patients with alcohol abuse disorder. A significant reduction in the severity of the dependence was observed only in the subgroups of participants with cocaine and alcohol use disorders. Conclusion Our study suggests that once-monthly LAI-aripiprazole retains its antipsychotic efficacy in patients with schizophrenia and a coexisting SUD and could be useful for the management of cocaine or alcohol use disorders in this population. |
| first_indexed | 2024-12-17T08:48:19Z |
| format | Article |
| id | doaj.art-18d10bedf41d46fab025b29236741135 |
| institution | Directory Open Access Journal |
| issn | 2199-1154 2198-9788 |
| language | English |
| last_indexed | 2024-12-17T08:48:19Z |
| publishDate | 2020-02-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Drugs - Real World Outcomes |
| spelling | doaj.art-18d10bedf41d46fab025b292367411352022-12-21T21:56:09ZengAdis, Springer HealthcareDrugs - Real World Outcomes2199-11542198-97882020-02-0171758310.1007/s40801-020-00178-8Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational StudyNestor Szerman0Ignacio Basurte-Villamor1Pablo Vega2Jose Martinez-Raga3Carlos Parro-Torres4Julia Cambra Almerge5Lara Grau-López6Mario De Matteis7Francisco Arias8Instituto Psiquiatría y Salud Mental, Hospital General Universitario Gregorio MarañónInstituto Psiquiatría y Salud Mental, Hospital General Universitario Gregorio MarañónInstituto de AdiccionesPsychiatry Department, University Hospital Dr. Peset, University of Valencia and University CEU-UCHPsychiatry Department, Hospital General Universitario Gregorio MarañónPsychiatry Department, “Proyecto Hombre”Addiction and Dual Diagnosis Unit, Department of Psychiatry, Vall d’Hebron University Hospital, CIBERSAMPsychiatry Department, Hospital General Universitario Gregorio MarañónPsychiatry Department, 12 de Octubre University HospitalAbstract Aim To evaluate the efficacy and impact of long-acting injectable (LAI) aripiprazole in patients with schizophrenia with a coexisting substance use disorder (SUD). Patients and methods A multicenter, observational, descriptive and retrospective study was conducted in patients with a DSM-5 diagnosis of schizophrenia who had a coexisting SUD and were treated with LAI-aripiprazole. Disease severity was evaluated with the Clinical Global Impression (CGI) severity scale for schizophrenia, daily functioning and disability were evaluated with the World Health Organisation Disability Assessment Scale (WHODAS-2.0), and the severity of the addiction was evaluated with the Severity of Dependence Scale (SDS). Results The sample included 40 patients. Overall, after 6 months of treatment with LAI-aripiprazole at a dose of 400 mg/4 weeks in 77.5% of the patients, we observed significant improvement in the psychopathological symptoms, with a reduction of over 30% in the scores of the five CGI-severity scales. The WHODAS-2.0 mean (standard deviation) score was also significantly reduced from 57.6 (8.2) to 42.3 (4.3) points (p < 0.001). Regarding SUDs, after 6 months of treatment, substance use was stopped in 5 of the 9 patients with cocaine use disorder and in 3 of the 16 patients with alcohol abuse disorder. A significant reduction in the severity of the dependence was observed only in the subgroups of participants with cocaine and alcohol use disorders. Conclusion Our study suggests that once-monthly LAI-aripiprazole retains its antipsychotic efficacy in patients with schizophrenia and a coexisting SUD and could be useful for the management of cocaine or alcohol use disorders in this population.https://doi.org/10.1007/s40801-020-00178-8 |
| spellingShingle | Nestor Szerman Ignacio Basurte-Villamor Pablo Vega Jose Martinez-Raga Carlos Parro-Torres Julia Cambra Almerge Lara Grau-López Mario De Matteis Francisco Arias Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study Drugs - Real World Outcomes |
| title | Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study |
| title_full | Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study |
| title_fullStr | Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study |
| title_full_unstemmed | Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study |
| title_short | Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study |
| title_sort | once monthly long acting injectable aripiprazole for the treatment of patients with schizophrenia and co occurring substance use disorders a multicentre observational study |
| url | https://doi.org/10.1007/s40801-020-00178-8 |
| work_keys_str_mv | AT nestorszerman oncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT ignaciobasurtevillamor oncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT pablovega oncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT josemartinezraga oncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT carlosparrotorres oncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT juliacambraalmerge oncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT laragraulopez oncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT mariodematteis oncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT franciscoarias oncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy |